» Articles » PMID: 38261126

Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks

Abstract

Rates of contralateral mastectomy (CM) among patients with unilateral breast cancer have been increasing in the United States. In this Society of Surgical Oncology position statement, we review the literature addressing the indications, risks, and benefits of CM since the society's 2017 statement. We held a virtual meeting to outline key topics and then conducted a literature search using PubMed to identify relevant articles. We reviewed the articles and made recommendations based on group consensus. Patients consider CM for many reasons, including concerns regarding the risk of contralateral breast cancer (CBC), desire for improved cosmesis and symmetry, and preferences to avoid ongoing screening, whereas surgeons primarily consider CBC risk when making a recommendation for CM. For patients with a high risk of CBC, CM reduces the risk of new breast cancer, however it is not known to convey an overall survival benefit. Studies evaluating patient satisfaction with CM and reconstruction have yielded mixed results. Imaging with mammography within 12 months before CM is recommended, but routine preoperative breast magnetic resonance imaging is not; there is also no evidence to support routine postmastectomy imaging surveillance. Because the likelihood of identifying an occult malignancy during CM is low, routine sentinel lymph node surgery is not recommended. Data on the rates of postoperative complications are conflicting, and such complications may not be directly related to CM. Adjuvant therapy delays due to complications have not been reported. Surgeons can reduce CM rates by encouraging shared decision making and informed discussions incorporating patient preferences.

Citing Articles

Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks.

Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E Ann Surg Oncol. 2024; 32(2):899-911.

PMID: 39538100 DOI: 10.1245/s10434-024-16484-2.

References
1.
Nelson J, Rubenstein R, Haglich K, Chu J, Yin S, Stern C . Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets. JAMA Surg. 2022; 157(8):702-711. PMC: 9178497. DOI: 10.1001/jamasurg.2022.2065. View

2.
Arthur D, Winter K, Kuerer H, Haffty B, Cuttino L, Todor D . Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA Oncol. 2019; 6(1):75-82. PMC: 6902101. DOI: 10.1001/jamaoncol.2019.4320. View

3.
Boughey J, Rosenkranz K, Ballman K, McCall L, Haffty B, Cuttino L . Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). J Clin Oncol. 2023; 41(17):3184-3193. PMC: 10256355. DOI: 10.1200/JCO.22.02553. View

4.
van Maaren M, de Munck L, de Bock G, Jobsen J, van Dalen T, Linn S . 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016; 17(8):1158-1170. DOI: 10.1016/S1470-2045(16)30067-5. View

5.
Hunt K, Euhus D, Boughey J, Chagpar A, Feldman S, Hansen N . Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Ann Surg Oncol. 2016; 24(2):375-397. DOI: 10.1245/s10434-016-5688-z. View